The infections caused in Acute Myeloid Leukemia patients after chemotherapy
Not Applicable
- Conditions
- Health Condition 1: C92A- Acute myeloid leukemia with multilineage dysplasia
- Registration Number
- CTRI/2022/10/046636
- Lead Sponsor
- Jamia Hamdard
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with newly diagnosed AML
Exclusion Criteria
APML
Patients whose records are incomplete or not available
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the spectrum of infections in patients with De novo Acute Myeloid Leukemia <br/ ><br>undergoing induction chemotherapy.Timepoint: Day 7, 14, 28, First consolidation and 28 days, second consolidation and 28 days
- Secondary Outcome Measures
Name Time Method To estimate the incidence of toxicities and adverse events following the chemotherapy <br/ ><br>treatment and their managementTimepoint: Day 7, 14, and 28;To study the mortality during after induction chemotherapy.Timepoint: Day 7, 14, and 28;To study the outcome of AML patients (Remission rate and survival rate)Timepoint: Day 7, 14, and 28